
    
      This trial is a multicenter, single-arm, phase 2 study of pembrolizumab in combination with
      olaparib in recurrent or metastatic cervical cancer patients who had disease progression
      during or after platinum-based chemotherapy.

      This study is planned to enroll 28 patients eligible for participation from multiple study
      sites in Japan.
    
  